Nov13, 2018: PrecisionNanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) entered into a license and supply agreement for the scale-up, technology transfer and supporting GMP manufacturing of Entos’ lead candidate nanoparticle drug product; Fusogenix. Entos will use the NanoAssemblr® Blaze™ instrument for preclinical toxicology studies and transition to the NanoAssemblr® Scale-Up system for GMP manufacturing of Fusogenix for clinical studies. The PNI and the Entos teams are working together to develop a complete solution with custom instrumentation, expertise and services for nanoparticle formulation scale-up to transition smoothly and efficiently towards clinical manufacturing for phase I study.
“We have been using the NanoAssemblr® Benchtop instrument in our research and are excited to work with PNI as we progress our lead candidate drug product through late stage preclinical and clinical phases of development”
John Lewis, co-founder and CEO of Entos
With over 250 systems placed worldwide, PNI’s NanoAssemblr® platform is used by over 85 pharma and biotech companies for the development and scalable manufacture of nanoparticle therapeutics.
“PNI is committed to supporting its customers by providing a customized and complete solution that includes instrumentation, expertise and services. We look forward to working with Entos in helping progress their first program through GMP manufacturing and clinical studies”
James Taylor, co-founder and CEO of PNI.
The PNI proprietary NanoAssemblr® Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.